UM

Browse/Search Results:  1-2 of 2 Help

Filters    
Selected(0)Clear Items/Page:    Sort:
Substantial protection against MPTP-associated Parkinson's neurotoxicity in vitro and in vivo by anti-cancer agent SU4312 via activation of MEF2D and inhibition of MAO-B Journal article
NEUROPHARMACOLOGY, 2017,Volume: 126,Page: 12-24
Authors:  Guo, Baojian;  Hu, Shengquan;  Zheng, Chengyou;  Wang, Hongyu;  Luo, Fangcheng;  Li, Haitao;  Cui, Wei;  Yang, Xifei;  Cui, Guozhen;  Mak, Shinghung;  Choi, Tony Chung-Lit;  Ma, Edmond Dik-Lung;  Wang, Yuqiang;  Lee, Simon Ming Yuen;  Zhang, Zaijun;  Han, Yifan
View  |  Adobe PDF(2766Kb)  |  Favorite  |  View/Download:432/9  |  Submit date:2018/10/31
Parkinson's disease  SU4312  Neuroprotection  Myocyte enhancer factor 2D  Monoamine oxidase-B  
Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells Journal article
ACTA PHARMACOLOGICA SINICA, 2017,Volume: 38,Issue: 11,Page: 1512-1520
Authors:  Jiang, Xiao-Ming;  Xu, Yu-Lian;  Huang, Mu-Yang;  Zhang, Le-Le;  Su, Min-Xia;  Chen, Xiuping;  Lu, Jin-Jian
Favorite  |  View/Download:26/0  |  Submit date:2018/10/30
Non-small Cell Lung Cancer  Egfr  Osimertinib  Pd-l1  Ubiquitin-proteasome System  Mg-132  Bortezomib  Gsk3 Beta  Licl